Please enable JavaScript.
Coggle requires JavaScript to display documents.
Psilocybin-assisted treatment for major depressive disorder - Coggle…
Psilocybin-assisted treatment for major depressive disorder
I. Introduction
A. Background information on the potential of psilocybin-assisted therapy for depression
B. Limited knowledge about long-term outcomes of such treatment
C. Aim of the study: To examine the efficacy and safety of psilocybin through a 12-month period in participants with moderate to severe MDD
II. Study Methodology
B. Follow-up duration: 12 months following the second psilocybin dose
C. Outcomes measured using the GRID-Hamilton Depression Rating Scale (GRID-HAMD)
A. Description of the randomized, waiting-list controlled study
Enrollment of 27 patients with moderate to severe unipolar depression
Randomization into immediate or delayed (8 weeks) treatment groups
Two doses of psilocybin administered with supportive psychotherapy
III. Key Findings
B. High rates of treatment response (⩾50% reduction in GRID-HAMD score from baseline) and remission (58%) at the 12-month follow-up
C. No serious adverse events related to psilocybin during the long-term follow-up period
D. Absence of unauthorized psilocybin use outside the study context
E. Influence of participant ratings of personal meaning, spiritual experience, and mystical experience on increased well-being at 12 months, although these factors did not predict improvement in depression
A. Consistent and substantial reductions in GRID-HAMD scores observed at multiple follow-up intervals (1 month, 3 months, 6 months, and 12 months)
IV. Conclusion
A. Implication of findings: Antidepressant effects of psilocybin-assisted therapy appear durable for at least 12 months following acute intervention in some patients
B. Note on the complexity of psychological factors and the interplay between well-being and depression improvement
C. Call for further research to confirm and expand on these findings, as well as explore the treatment's efficacy in a broader population
Gukasyan, Natalie et al. “Efficacy and Safety of Psilocybin-Assisted Treatment for Major Depressive Disorder: Prospective 12-Month Follow-Up.” Journal of psychopharmacology (Oxford) 36.2 (2022): 151–158. Web.
https://spc-flvc.primo.exlibrisgroup.com/permalink/01FALSC_SPC/1veuhe4/cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8864328